Multi-ancestry GWAS analysis identifies two novel loci associated with diabetic eye disease and highlights APOL1 as a high risk locus in patients with diabetic macular edema

PLoS Genet. 2023 Aug 16;19(8):e1010609. doi: 10.1371/journal.pgen.1010609. eCollection 2023 Aug.

Abstract

Diabetic retinopathy (DR) is a common complication of diabetes. Approximately 20% of DR patients have diabetic macular edema (DME) characterized by fluid leakage into the retina. There is a genetic component to DR and DME risk, but few replicable loci. Because not all DR cases have DME, we focused on DME to increase power, and conducted a multi-ancestry GWAS to assess DME risk in a total of 1,502 DME patients and 5,603 non-DME controls in discovery and replication datasets. Two loci reached GWAS significance (p<5x10-8). The strongest association was rs2239785, (K150E) in APOL1. The second finding was rs10402468, which co-localized to PLVAP and ANKLE1 in vascular / endothelium tissues. We conducted multiple sensitivity analyses to establish that the associations were specific to DME status and did not reflect diabetes status or other diabetic complications. Here we report two novel loci for risk of DME which replicated in multiple clinical trial and biobank derived datasets. One of these loci, containing the gene APOL1, is a risk factor in African American DME and DKD patients, indicating that this locus plays a broader role in diabetic complications for multiple ancestries. Trial Registration: NCT00473330, NCT00473382, NCT03622580, NCT03622593, NCT04108156.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apolipoprotein L1 / genetics
  • Diabetes Mellitus*
  • Diabetic Retinopathy* / complications
  • Diabetic Retinopathy* / genetics
  • Genome-Wide Association Study
  • Humans
  • Macular Edema* / complications
  • Macular Edema* / genetics
  • Risk Factors

Substances

  • Apolipoprotein L1
  • APOL1 protein, human

Associated data

  • ClinicalTrials.gov/NCT03622580
  • ClinicalTrials.gov/NCT00473382
  • ClinicalTrials.gov/NCT03622593
  • ClinicalTrials.gov/NCT04108156
  • ClinicalTrials.gov/NCT00473330

Grants and funding

Funding for this project was from F. Hoffmann - La Roche. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.